Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Cyclopentolate
Overview
What is Cyclopentolate?
Cyclopentolate Hydrochloride Ophthalmic Solution, USP is an anticholinergic prepared as a sterile, borate buffered, solution for topical ocular use. The active ingredient is represented by the structural formula:
Molecular Weight=327.85
Molecular Formula: CHNO•HCl
Established name: Cyclopentolate Hydrochloride
Chemical name: 2-(Dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate hydrochloride
Each mL contains: Active:
Inactives:
Preservative:
What does Cyclopentolate look like?
What are the available doses of Cyclopentolate?
Sorry No records found.
What should I talk to my health care provider before I take Cyclopentolate?
Sorry No records found
How should I use Cyclopentolate?
Cyclopentolate hydrochloride is used to produce mydriasis and cycloplegia.
Adults:
Children:
Small Infants:
What interacts with Cyclopentolate?
Should not be used when untreated narrow-angle glaucoma, or untreated anatomically narrow angles are present, or if the patient is hypersensitive to any component of this preparation.
What are the warnings of Cyclopentolate?
Local necrosis has
been associated with the use of subcutaneous or intradermal use of
intravenous diphenhydramine.
FOR TOPICAL APPLICATION IN THE EYENOT FOR INJECTION. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% Cyclopentolate hydrochloride solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes following instillation.
Mydriatics may produce a transient elevation of intraocular pressure.
What are the precautions of Cyclopentolate?
General
The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome and in those predisposed to angle-closure glaucoma.
Information for Patients
Do not touch dropper tip to any surface, as this may contaminate the solution. A transient burning sensation may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination.
Drug Interactions
Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies in animals or humans have not been conducted to evaluate the carcinogenic potential of cyclopentolate hydrochloride ophthalmic solution, USP.
Pregnancy
Pregnancy Category C. Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman.
Pediatric Use
Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination. Observe infants closely for at least 30 minutes (See ).
Geriatric Use
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
What are the side effects of Cyclopentolate?
Ocular:
Non-ocular:
What should I look out for while using Cyclopentolate?
Should not be used when untreated narrow-angle glaucoma, or untreated anatomically narrow angles are present, or if the patient is hypersensitive to any component of this preparation.
FOR TOPICAL APPLICATION IN THE EYENOT FOR INJECTION. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% Cyclopentolate hydrochloride solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes following instillation.
Mydriatics may produce a transient elevation of intraocular pressure.
What might happen if I take too much Cyclopentolate?
Excessive dosage may produce behavioral disturbances, tachycardia, hyperpyrexia, hypertension, elevated intraocular pressure, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Patients exhibiting signs of overdosage should receive supportive care and monitoring.
How should I store and handle Cyclopentolate?
Storage:Revised: 10/2013© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.® marks owned by Allergan, Inc.Patented. See: www.allergan.com/products/patent_noticesMade in the U.S.A. Array71654PY10 Storage:Revised: 10/2013© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.® marks owned by Allergan, Inc.Patented. See: www.allergan.com/products/patent_noticesMade in the U.S.A. Array71654PY10 Storage:Revised: 10/2013© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.® marks owned by Allergan, Inc.Patented. See: www.allergan.com/products/patent_noticesMade in the U.S.A. Array71654PY10 Storage:Revised: 10/2013© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.® marks owned by Allergan, Inc.Patented. See: www.allergan.com/products/patent_noticesMade in the U.S.A. Array71654PY10 Storage:Revised: 10/2013© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.® marks owned by Allergan, Inc.Patented. See: www.allergan.com/products/patent_noticesMade in the U.S.A. Array71654PY10 Cyclopentolate Hydrochloride Ophthalmic Solution, USP 0.5% is supplied in multiple–dose plastic Boston Round Natural LDPE bottle with a 15 mm LLDPE dropper-tip and 15 mm polypropylene red cap.NDC 17478-096-15 15 mL fill/15 mL bottle Storage:Akorn LogoManufactured by: Lake Forest, IL 60045CPA0N Rev. 06/16Cyclopentolate Hydrochloride Ophthalmic Solution, USP 0.5% is supplied in multiple–dose plastic Boston Round Natural LDPE bottle with a 15 mm LLDPE dropper-tip and 15 mm polypropylene red cap.NDC 17478-096-15 15 mL fill/15 mL bottle Storage:Akorn LogoManufactured by: Lake Forest, IL 60045CPA0N Rev. 06/16Cyclopentolate Hydrochloride Ophthalmic Solution, USP 0.5% is supplied in multiple–dose plastic Boston Round Natural LDPE bottle with a 15 mm LLDPE dropper-tip and 15 mm polypropylene red cap.NDC 17478-096-15 15 mL fill/15 mL bottle Storage:Akorn LogoManufactured by: Lake Forest, IL 60045CPA0N Rev. 06/16Cyclopentolate Hydrochloride Ophthalmic Solution, USP 0.5% is supplied in multiple–dose plastic Boston Round Natural LDPE bottle with a 15 mm LLDPE dropper-tip and 15 mm polypropylene red cap.NDC 17478-096-15 15 mL fill/15 mL bottle Storage:Akorn LogoManufactured by: Lake Forest, IL 60045CPA0N Rev. 06/16Cyclopentolate Hydrochloride Ophthalmic Solution, USP 0.5% is supplied in multiple–dose plastic Boston Round Natural LDPE bottle with a 15 mm LLDPE dropper-tip and 15 mm polypropylene red cap.NDC 17478-096-15 15 mL fill/15 mL bottle Storage:Akorn LogoManufactured by: Lake Forest, IL 60045CPA0N Rev. 06/16
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing papillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.
Non-Clinical Toxicology
Should not be used when untreated narrow-angle glaucoma, or untreated anatomically narrow angles are present, or if the patient is hypersensitive to any component of this preparation.FOR TOPICAL APPLICATION IN THE EYENOT FOR INJECTION. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% Cyclopentolate hydrochloride solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes following instillation.
Mydriatics may produce a transient elevation of intraocular pressure.
General
The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome and in those predisposed to angle-closure glaucoma.
Information for Patients
Do not touch dropper tip to any surface, as this may contaminate the solution. A transient burning sensation may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination.
Drug Interactions
Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies in animals or humans have not been conducted to evaluate the carcinogenic potential of cyclopentolate hydrochloride ophthalmic solution, USP.
Pregnancy
Pregnancy Category C. Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman.
Pediatric Use
Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination. Observe infants closely for at least 30 minutes (See ).
Geriatric Use
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Ocular:
Non-ocular:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
518Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).